BIO-TECHNE Corp Net Cash Provided by (Used in) Investing Activities, Continuing Operations
BIO-TECHNE Corp (TECH) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$305.95 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-09-07
- BIO-TECHNE Corp net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$4.70M.
- BIO-TECHNE Corp net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $4.00K.
- BIO-TECHNE Corp net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$32.98M.
- BIO-TECHNE Corp net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$268.28M.
- BIO-TECHNE Corp net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$305.95M.
- BIO-TECHNE Corp net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$107.57M.
- BIO-TECHNE Corp net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$426.49M, a 958.34% decline from fiscal 2014.
- BIO-TECHNE Corp net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $49.69M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|
| 2017-06-30 | -$4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | -$4.70M derived: sum of 2 quarters · filed 2017-09-07 | -$37.67M derived: sum of 3 quarters · filed 2017-09-07 | -$305.95M 10-K · filed 2017-09-07 | |
| 2017-03-31 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | -$32.97M derived: sum of 2 quarters · filed 2017-05-10 | -$301.25M 10-Q · filed 2017-05-10 | -$304.87M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2016-12-31 | -$32.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | -$301.26M 10-Q · filed 2017-02-09 | -$304.88M derived: sum of 3 quarters · filed 2017-09-07 | -$318.86M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2016-09-30 | -$268.28M 10-Q · filed 2016-11-09 | -$271.90M derived: sum of 2 quarters · filed 2017-09-07 | -$285.89M derived: sum of 3 quarters · filed 2017-09-07 | -$290.69M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2016-06-30 | -$3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | -$17.60M derived: sum of 2 quarters · filed 2017-09-07 | -$22.41M derived: sum of 3 quarters · filed 2017-09-07 | -$107.57M 10-K · filed 2017-09-07 | |
| 2016-03-31 | -$13.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | -$18.79M derived: sum of 2 quarters · filed 2017-05-10 | -$103.95M 10-Q · filed 2017-05-10 | -$109.47M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-12-31 | -$4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | -$89.97M 10-Q · filed 2017-02-09 | -$95.49M derived: sum of 3 quarters · filed 2017-09-07 | -$98.64M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-09-30 | -$85.16M 10-Q · filed 2016-11-09 | -$90.68M derived: sum of 2 quarters · filed 2017-09-07 | -$93.83M derived: sum of 3 quarters · filed 2017-09-07 | -$156.90M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-06-30 | -$5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | -$8.67M derived: sum of 2 quarters · filed 2017-09-07 | -$71.74M derived: sum of 3 quarters · filed 2017-09-07 | -$426.49M 10-K · filed 2017-09-07 | -$426.49M 10-K · filed 2015-08-31 |
| 2015-03-31 | -$3.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10 | -$66.22M derived: sum of 2 quarters · filed 2016-05-10 | -$420.97M 10-Q · filed 2016-05-10 | -$257.29M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-12-31 | -$63.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | -$417.82M 10-Q · filed 2016-02-09 | -$254.14M derived: sum of 3 quarters · filed 2016-08-29 | -$254.22M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-09-30 | -$354.75M 10-Q · filed 2015-11-09 | -$191.07M derived: sum of 2 quarters · filed 2016-08-29 | -$191.15M derived: sum of 3 quarters · filed 2016-08-29 | -$199.93M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-06-30 | $163.69M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29 | $163.60M derived: sum of 2 quarters · filed 2016-08-29 | $154.82M derived: sum of 3 quarters · filed 2016-08-29 | $49.69M 10-K · filed 2016-08-29 | |
| 2014-03-31 | -$81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | -$8.86M derived: sum of 2 quarters · filed 2015-05-11 | -$114.00M 10-Q · filed 2015-05-11 | ||
| 2013-12-31 | -$8.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09 | -$113.92M 10-Q · filed 2015-02-09 | |||
| 2013-09-30 | -$105.13M 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | -$31.20M 10-K · filed 2015-08-31 | ||||
| 2012-06-30 | -$21.67M 10-K · filed 2014-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |